{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-034316","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.180483+00:00","generated_at":"2026-06-09T23:49:20.497725+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cumberland Pharma announces pediatric Vibativ safety study publication","bullets":["First clinical study of Vibativ in children 2–17; single 10 mg/kg dose safe with no serious adverse events.","Published in Antimicrobial Agents and Chemotherapy; 22 patients enrolled.","Study found lower drug exposure in children vs adults, informing future dosing.","Vibativ is FDA-approved for adult HABP/VABP and cSSSIs caused by gram-positive bacteria."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-034316","json":"https://secwatch.observer/filing/0001628280-23-034316.json","markdown":"https://secwatch.observer/filing/0001628280-23-034316.md","text":"https://secwatch.observer/filing/0001628280-23-034316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/0001628280-23-034316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/cpix-20231013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:49:20.497725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}